Praxis Medicine vs OpenEvidence (2026): European Newcomer vs US Clinical AI Giant
At a Glance
Who is it for?
Praxis Medicine:European clinicians (waitlist)
OpenEvidence:US physicians (757K+ clinicians, 40%+ daily use)
Why choose Praxis Medicine?
- European-native: Stockholm HQ, UK guideline grounding
- 70M SEK from Balderton Capital + Creandum
- Voi co-founder Douglas Stark
- Lists NICE, CKS, NHS Digital, Europe PMC
- NHS Developer Community engagement
- No EU AI Act regulatory uncertainty (European-native)
Why choose OpenEvidence?
- **$12B valuation; $700M+ funding** (Sequoia, GV, NVIDIA, Kleiner Perkins)
- **NEJM, JAMA, Cochrane, NCCN partnerships**
- **Epic EHR embedded** (Mount Sinai, Sutter Health)
- **$100M ARR** (Jan 2026)
- **757,000+ clinician users**
- Proprietary models on peer-reviewed literature
Feature Comparison
| Capability | Praxis Medicine | OpenEvidence |
|---|---|---|
| Geographic Availability | European-focused; UK-guideline-first | **US only** — withdrew from EU/UK (April 2026) |
| Product Status | Pre-launch / waitlist | **Live and scaled in US** |
| Guideline Sources | NICE, CKS, NHS Digital, Europe PMC | NEJM, JAMA, Cochrane, NCCN, FDA, ACC, ADA, AAFP |
| E H R Integration | NHS integration signals (early) | **Epic-embedded (Mount Sinai, Sutter Health)** |
| Regulatory Status | No public device registration | US-focused; cited EU AI Act uncertainty for withdrawal |
| Funding | 70M SEK (~€6M) | **$700M+** |
In-Depth Analysis
Overview
OpenEvidence proved that clinical AI search is a massive category: $12B valuation, $100M ARR, NEJM/JAMA partnerships, Epic EHR integration. Then it withdrew from Europe, citing EU AI Act regulatory uncertainty.
Praxis Medicine is positioned to fill part of that European gap — founded by a proven operator (Douglas Stark, Voi), backed by top-tier European VCs (Balderton, Creandum), and explicitly grounded in UK guideline sources.
Neither is available for European clinicians to use today. For a live, MHRA-registered UK clinical AI with guideline retrieval, exams, and calculators, see iatroX.
Public information as of 3 May 2026. Trademarks belong to their owners.
Looking for a faster way?
While Praxis Medicine and OpenEvidence are powerful tools, iatroX offers a free, AI-driven alternative focused specifically on rapid UK guideline retrieval and exam prep.
Use-Cases
UK/EU Clinician Wanting Clinical AI Now
When to choose Praxis Medicine
- Not yet shipping.
When to choose OpenEvidence
- **Withdrew from EU/UK.** Not available in Europe.
US Physician
When to choose Praxis Medicine
- Not relevant.
When to choose OpenEvidence
- **Winner.** Dominant US clinical AI with NEJM/JAMA content and Epic integration.
European Clinical AI Investment Thesis
When to choose Praxis Medicine
- Validates the European opportunity post-OpenEvidence withdrawal.
When to choose OpenEvidence
- Proved the demand side ($100M ARR, 40%+ daily physician use) before withdrawing.